Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 13, 2017 - Issue 3
Submit an article Journal homepage
5,523
Views
81
CrossRef citations to date
0
Altmetric
Research Papers

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

I. V. DolzhikovaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
O. V. ZubkovaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
A. I. TukhvatulinFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
A. S. DzharullaevaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
N. M. TukhvatulinaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
D. V. ShcheblyakovFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
M. M. ShmarovFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
E. A. TokarskayaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
Y. V. SimakovaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
D. A. EgorovaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
D. N. ScherbininFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
I. L. TutykhinaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
A. A. LysenkoFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
A. V. KostarnoyFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
P. G. GanchevaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
T. A. OzharovskayaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
B. V. BeluginFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
L. V. KolobukhinaFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
,
V. B. Pantyukhov48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
S. I. Syromyatnikova48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
I. V. Shatokhina48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
T. V. Sizikova48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
I. G. Rumyantseva48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
A. F. Andrus48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
N. V. Boyarskaya48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
A. N. Voytyuk48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
V. F. BabiraNo. 7 Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense, Posad-7, Russia
,
S. V. VolchikhinaNo. 7 Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense, Posad-7, Russia
,
D. A. Kutaev48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
A. N. Bel'skihMilitary Medical Academy named after S. M. Kirov, Ministry of Defense, Saint Petersburg, Russia
,
K. V. ZhdanovMilitary Medical Academy named after S. M. Kirov, Ministry of Defense, Saint Petersburg, Russia
,
S. M. ZakharenkoMilitary Medical Academy named after S. M. Kirov, Ministry of Defense, Saint Petersburg, Russia
,
S. V. Borisevich48 Central Research Institute, Ministry of Defense, Sergiev Posad-6, Russia
,
D. Y. LogunovFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, RussiaCorrespondence[email protected]
,
B. S. NaroditskyFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
&
A. L. GintsburgFederal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow, Russia
 show all
Pages 613-620 | Received 06 Jun 2016, Accepted 15 Sep 2016, Published online: 02 Feb 2017

Citations (81)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Kyle O’Donnell & Andrea Marzi. (2020) The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. Expert Review of Vaccines 19:3, pages 267-277.
Read now
Keesha M. Matz, Andrea Marzi & Heinz Feldmann. (2019) Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Review of Vaccines 18:12, pages 1229-1242.
Read now
John J. Suschak & Connie S. Schmaljohn. (2019) Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Human Vaccines & Immunotherapeutics 15:10, pages 2359-2377.
Read now
Franck J. D. Mennechet, Océane Paris, Aline Raissa Ouoba, Sofia Salazar Arenas, Sodiomon B. Sirima, Guy R. Takoudjou Dzomo, Amidou Diarra, Isidore T Traore, Dramane Kania, Karsten Eichholz, Eric A. Weaver, Edouard Tuaillon & Eric J. Kremer. (2019) A review of 65 years of human adenovirus seroprevalence. Expert Review of Vaccines 18:6, pages 597-613.
Read now
Raj Kumar Singh, Kuldeep Dhama, Yashpal Singh Malik, Muthannan Andavar Ramakrishnan, Kumaragurubaran Karthik, Rekha Khandia, Ruchi Tiwari, Ashok Munjal, Mani Saminathan, Swati Sachan, Perumal Arumugam Desingu, Jobin Jose Kattoor, Hafiz M.N. Iqbal & Sunil Kumar Joshi. (2017) Ebola virus – epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans – an update on its 40 year's journey. Veterinary Quarterly 37:1, pages 98-135.
Read now

Articles from other publishers (76)

Anna V. Kovyrshina, Tatiana E. Sizikova, Vitaliy N. Lebedev, Sergey V. Borisevich, Inna V. Dolzhikova, Denis Yu. Logunov & Alexander L. Gintsburg. (2023) Vaccines to prevent Ebola virus disease: current challenges and perspectives. Problems of Virology 68:5, pages 372-384.
Crossref
Junqi Zhang, Baozeng Sun, Wenyang Shen, Zhenjie Wang, Yang Liu, Yubo Sun, Jiaxing Zhang, Ruibo Liu, Yongkai Wang, Tianyuan Bai, Zilu Ma, Cheng Luo, Xupeng Qiao, Xiyang Zhang, Shuya Yang, Yuanjie Sun, Dongbo Jiang & Kun Yang. (2023) In Silico Analyses, Experimental Verification and Application in DNA Vaccines of Ebolavirus GP-Derived pan-MHC-II-Restricted Epitopes. Vaccines 11:10, pages 1620.
Crossref
Avinash Teli, Pooja Rathore, Rohit Kumar & Mohammad Shamshir Alam. (2023) Vaccine equity and access: A comparative assessment of Covaxin, Covishield, and Sputnik V.. Indian Journal of Pharmacy and Pharmacology 10:2, pages 76-88.
Crossref
Hong-Qing Zhang, Qiu-Yan Zhang, Zhi-Ming Yuan & Bo Zhang. (2023) The potential epidemic threat of Ebola virus and the development of a preventive vaccine. Journal of Biosafety and Biosecurity 5:2, pages 67-78.
Crossref
Shen Wang, Bo Liang, Weiqi Wang, Ling Li, Na Feng, Yongkun Zhao, Tiecheng Wang, Feihu Yan, Songtao Yang & Xianzhu Xia. (2023) Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduction and Targeted Therapy 8:1.
Crossref
Sahil Jain, Svetlana Khaiboullina, Ekaterina Martynova, Sergey Morzunov & Manoj Baranwal. (2023) Epidemiology of Ebolaviruses from an Etiological Perspective. Pathogens 12:2, pages 248.
Crossref
Sumira Malik, Shristi Kishore, Sagnik Nag, Archna Dhasmana, Subham Preetam, Oishi Mitra, Darwin A. León-Figueroa, Aroop Mohanty, Vijay Kumar Chattu, Marjan Assefi, Bijaya K. Padhi & Ranjit Sah. (2023) Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges. Vaccines 11:2, pages 268.
Crossref
Ruth Hunegnaw, Andrea S. Vicari & Nancy J. Sullivan. 2023. Plotkin's Vaccines. Plotkin's Vaccines 311 329.e6 .
A. A. Soldatov, D. V. Gorenkov, V. A. Merkulov & V. P. Bondarev. (2022) Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. Biological Products. Prevention, Diagnosis, Treatment 22:4, pages 361-381.
Crossref
Roberto Biselli, Roberto Nisini, Florigio Lista, Alberto Autore, Marco Lastilla, Giuseppe De Lorenzo, Mario Stefano Peragallo, Tommaso Stroffolini & Raffaele D’Amelio. (2022) A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health. Biomedicines 10:8, pages 2050.
Crossref
Naina McCann, Daniel O’Connor, Teresa Lambe & Andrew J Pollard. (2022) Viral vector vaccines. Current Opinion in Immunology 77, pages 102210.
Crossref
Gennadiy G. Onischenko & Sergey V. Borisevich. (2022) The Analysis of Anti-Epidemic Measures Carried Out in the Russian Federation in the Context of the COVID-19 Pandemic. Annals of the Russian academy of medical sciences 77:3, pages 172-180.
Crossref
Thomas L. RudgeJr.Jr., Nicholas J. Machesky, Karen A. Sankovich, Erin E. Lemmon, Christopher S. Badorrek, Rachel Overman, Nancy A. Niemuth & Michael S. Anderson. (2022) Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination—Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay. Vaccines 10:8, pages 1211.
Crossref
Ishan Garg, Abu Baker Sheikh, Suman Pal & Rahul Shekhar. (2022) Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. Infectious Disease Reports 14:4, pages 537-546.
Crossref
Miriam Ting & Jon B. Suzuki. (2022) Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. International Journal of Translational Medicine 2:2, pages 230-241.
Crossref
Jae Kyung Lee & Ok Sarah Shin. (2022) Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. Journal of Yeungnam Medical Science 39:2, pages 89-97.
Crossref
Courtney L. Finch, Christian Martinez, Elizabeth Leffel, Mario H. Skiadopoulos, Adam Hacker, Betty Mwesigwa, Diadié Maïga, Ian Mugisa, Grant Munkwase & Roxana Rustomjee. (2022) Vaccine Licensure in the Absence of Human Efficacy Data. Vaccines 10:3, pages 368.
Crossref
Robert Markewitz, David Juhl, Daniela Pauli, Siegfried Görg, Ralf Junker, Jan Rupp, Sarah Engel, Katja Steinhagen, Victor Herbst, Dorinja Zapf, Christina Krüger, Christian Brockmann, Frank Leypoldt, Justina Dargvainiene, Benjamin Schomburg, Shahpour Sharifzadeh, Lukas Salek Nejad, Klaus-Peter Wandinger & Malte Ziemann. (2022) Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Frontiers in Immunology 13.
Crossref
Sepehr Siahvoshi, Emad Movahed & Kimia Ghods. (2022) Common Side Effects of COVID-19 Vaccines Used in Iran: A Review. Annals of Military and Health Sciences Research 19:4.
Crossref
O. M. Drapkina, S. A. Burns, A. Yu. Gorshkov, V. N. Shishkova, L. N. Ryzhakova, O. A. Litinskaya, A. A. Ivanova, A. V. Veretennikova, V. S. Bashnyak & E. Yu. Tatarevich. (2022) Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals. Cardiovascular Therapy and Prevention 20:8, pages 3124.
Crossref
Ilias B. Esmagambetov, Dmitriy V. Shcheblyakov, Daria A. Egorova, Olga L. Voronina, Artem A. Derkaev, Daria V. Voronina, Olga Popova, Ekaterina I. Ryabova, Dmitriy N. Shcherbinin, Ekaterina I. Aksenova, Andrey N. Semenov, Marina S. Kunda, Natalia N. Ryzhova, Olga V. Zubkova, Amir I. Tukhvatulin, Denis Yu. Logunov, Boris S. Naroditsky, Sergey V. Borisevich & Alexander L. Gintsburg. (2021) Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection. Acta Naturae 13:4, pages 53-63.
Crossref
Courtney Woolsey & Thomas W. Geisbert. (2021) Current state of Ebola virus vaccines: A snapshot. PLOS Pathogens 17:12, pages e1010078.
Crossref
Abdul Ahad, Sabahat Mahnoor, Muhammad Zaid, Muhammad Ali & Muhammad Sohail Afzal. (2022) Ebolavirus: Infection, Vaccination and Control. Molecular Genetics, Microbiology and Virology 36:S1, pages S55-S64.
Crossref
Miriam Ting & Jon B. Suzuki. (2021) SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines 9:11, pages 1690.
Crossref
Farhang Babamahmoodi, Majid Saeedi, Reza Alizadeh-Navaei, Akbar Hedayatizadeh-Omran, Seyed Abbas Mousavi, Gasem Ovaise, Shirafkan Kordi, Zahra Akbari, Mazaher Azordeh, Fatemeh Ahangarkani & Ahmad Alikhani. (2021) Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Scientific Reports 11:1.
Crossref
Hadeel T. Al-Jighefee, Hoda Najjar, Muna Nizar Ahmed, Abeer Qush, Sara Awwad & Layla Kamareddine. (2021) COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. Vaccines 9:10, pages 1196.
Crossref
L. M. Khantimirova, D. V. Gorenkov, S. G. Guseva, V. A. Merkulov & A. A. Soldatov. (2021) Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines. BIOpreparations. Prevention, Diagnosis, Treatment 21:4, pages 212-224.
Crossref
Ashish Ranjan Sharma, Yeon-Hee Lee, Sudarshini Nath & Sang-Soo Lee. (2021) Recent developments and strategies of Ebola virus vaccines. Current Opinion in Pharmacology 60, pages 46-53.
Crossref
Pamela MolinaMarbel Torres Arias. (2021) Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias. Bionatura 3:3, pages 2091-2113.
Crossref
Samir Andrade Mendonça, Reka Lorincz, Paul Boucher & David T. Curiel. (2021) Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. npj Vaccines 6:1.
Crossref
L. Klimek, A. M. Chaker, M. Cuevas & S. Becker. (2021) COVID-19-Impfungen: Replizierend oder Nichtreplizierend?. Laryngo-Rhino-Otologie 100:08, pages 603-607.
Crossref
Shyh Poh Teo. (2021) Gam-COVID-Vac (Sputnik V): a heterologous adenoviral vector-based COVID-19 vaccine. Aging Pathobiology and Therapeutics 3:2, pages 43-45.
Crossref
Kannan Damodharan, Gandarvakottai Senthilkumar Arumugam, Suresh Ganesan, Mukesh Doble & Sathiah Thennarasu. (2021) A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Advances 11:33, pages 20006-20035.
Crossref
Alessio Danilo Inchingolo, Angelo Michele Inchingolo, Ioana Roxana Bordea, Giuseppina Malcangi, Edit Xhajanka, Antonio Scarano, Felice Lorusso, Marco Farronato, Gianluca Martino Tartaglia, Ciro Gargiulo Isacco, Grazia Marinelli, Maria Teresa D’Oria, Denisa Hazballa, Luigi Santacroce, Andrea Ballini, Maria Contaldo, Francesco Inchingolo & Gianna Dipalma. (2021) SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. Microorganisms 9:4, pages 793.
Crossref
Olivia Flynn, Kate Dillane, Juliane Sousa Lanza, Jennifer M. Marshall, Jing Jin, Sarah E. Silk, Simon J. Draper & Anne C. Moore. (2021) Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection. Vaccines 9:3, pages 299.
Crossref
Raquel L. RussellPeter PelkaBrian L. Mark. (2021) Frontrunners in the race to develop a SARS-CoV-2 vaccine. Canadian Journal of Microbiology 67:3, pages 189-212.
Crossref
Deborah Pushparajah, Salma Jimenez, Shirley Wong, Hibah Alattas, Nafiseh Nafissi & Roderick A. Slavcev. (2021) Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews 170, pages 113-141.
Crossref
Denis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov, Amir I Tukhvatulin, Olga V Zubkova, Alina S Dzharullaeva, Anna V Kovyrshina, Nadezhda L Lubenets, Daria M Grousova, Alina S Erokhova, Andrei G Botikov, Fatima M Izhaeva, Olga Popova, Tatiana A Ozharovskaya, Ilias B Esmagambetov, Irina A Favorskaya, Denis I Zrelkin, Daria V Voronina, Dmitry N Shcherbinin, Alexander S Semikhin, Yana V Simakova, Elizaveta A Tokarskaya, Daria A Egorova, Maksim M Shmarov, Natalia A Nikitenko, Vladimir A Gushchin, Elena A Smolyarchuk, Sergey K Zyryanov, Sergei V Borisevich, Boris S Naroditsky & Alexander L Gintsburg. (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet 397:10275, pages 671-681.
Crossref
Ian Jones & Polly Roy. (2021) Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet 397:10275, pages 642-643.
Crossref
Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Jorge Carrillo, Julià Blanco, Bonaventura Clotet & Nuria Izquierdo-Useros. (2021) SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Membranes 11:1, pages 64.
Crossref
Ameer Khusro & Chirom Aarti. 2021. Human Viruses: Diseases, Treatments and Vaccines. Human Viruses: Diseases, Treatments and Vaccines 143 162 .
Larisa I. Karpenko, Evgeny K. Apartsin, Sergei G. Dudko, Ekaterina V. Starostina, Olga N. Kaplina, Denis V. Antonets, Ekaterina A. Volosnikova, Boris N. Zaitsev, Anastasiya Yu. Bakulina, Aliya G. Venyaminova, Alexander A. Ilyichev & Sergei I. Bazhan. (2020) Cationic Polymers for the Delivery of the Ebola DNA Vaccine Encoding Artificial T-Cell Immunogen. Vaccines 8:4, pages 718.
Crossref
Nancy A. Niemuth, Thomas L. Rudge, Karen A. Sankovich, Michael S. Anderson, Nicholas D. Skomrock, Christopher S. Badorrek & Carol L. Sabourin. (2020) Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. PLOS ONE 15:10, pages e0241016.
Crossref
Sahil Jain, Svetlana F. Khaiboullina & Manoj Baranwal. (2020) Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. Pathogens 9:10, pages 850.
Crossref
Denis Y Logunov, Inna V Dolzhikova, Olga V Zubkova, Amir I Tukhvatulin, Dmitry V Shcheblyakov, Alina S Dzharullaeva, Daria M Grousova, Alina S Erokhova, Anna V Kovyrshina, Andrei G Botikov, Fatima M Izhaeva, Olga Popova, Tatiana A Ozharovskaya, Ilias B Esmagambetov, Irina A Favorskaya, Denis I Zrelkin, Daria V Voronina, Dmitry N Shcherbinin, Alexander S Semikhin, Yana V Simakova, Elizaveta A Tokarskaya, Nadezhda L Lubenets, Daria A Egorova, Maksim M Shmarov, Natalia A Nikitenko, Lola F Morozova, Elena A Smolyarchuk, Evgeny V Kryukov, Vladimir F Babira, Sergei V Borisevich, Boris S Naroditsky & Alexander L Gintsburg. (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet 396:10255, pages 887-897.
Crossref
Emanuele Sasso, Anna Morena D’Alise, Nicola Zambrano, Elisa Scarselli, Antonella Folgori & Alfredo Nicosia. (2020) New viral vectors for infectious diseases and cancer. Seminars in Immunology 50, pages 101430.
Crossref
Feng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, Li-Hua Hou, Wen-Juan Wang, Jing-Xin Li, Shi-Po Wu, Bu-Sen Wang, Zhao Wang, Lei Wang, Si-Yue Jia, Hu-Dachuan Jiang, Ling Wang, Tao Jiang, Yi Hu, Jin-Bo Gou, Sha-Bei Xu, Jun-Jie Xu, Xue-Wen Wang, Wei Wang & Wei Chen. (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet 395:10240, pages 1845-1854.
Crossref
Lathika Valliyott, Ranjeet Dungdung & Rajendra Pilankatta. (2020) Semi-quantification of antibody-dependent enhancement (ADE) in the uptake of Adenovirus serotype 5 into THP-1 cells. Analytical Biochemistry 591, pages 113568.
Crossref
Dmitry Shcheblyakov, Ilias Esmagambetov, Pavel Simakin, Ludmila Kostina, Alexey Kozlov, Valeryi Tsibezov, Tatyana Grebennikova, Dmitriy Chifanov, Irina Rumyantseva, Natalia Boyarskaya, Tatiana Sizikova, Natalia Shagarova, Аlexandr Andrus, Irina Shatohina, Svetlana Syromyatnikova, Alexey Kovalchuk, Vladimir Pantyukhov, Sergey Borisevich, Olga Zubkova, Amir Tukhvatulin, Denis Logunov, Boris Naroditsky & Alexandr Gintsburg. (2019) Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection. Antiviral Research 172, pages 104617.
Crossref
Muhammad Usman Mirza, Michiel Vanmeert, Amjad Ali, Kanzal Iman, Matheus Froeyen & Muhammad Idrees. (2019) Perspectives towards antiviral drug discovery against Ebola virus. Journal of Medical Virology 91:12, pages 2029-2048.
Crossref
Jean-François Gélinas, Hiva Azizi, Sascha Kiesslich, Stéphane Lanthier, Jannie Perdersen, Parminder S. Chahal, Sven Ansorge, Gary Kobinger, Rénald Gilbert & Amine A. Kamen. (2019) Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. Vaccine 37:44, pages 6624-6632.
Crossref
Wakako FuruyamaAndrea Marzi. (2019) Ebola Virus: Pathogenesis and Countermeasure Development. Annual Review of Virology 6:1, pages 435-458.
Crossref
Giada Mattiuzzo, Emma M. Bentley & Mark Page. (2019) The Role of Reference Materials in the Research and Development of Diagnostic Tools and Treatments for Haemorrhagic Fever Viruses. Viruses 11:9, pages 781.
Crossref
Blaise Genton. (2019) Ebola vaccines: ready to use for humanitarian health workers?. Journal of Travel Medicine 26:5.
Crossref
Thomas L. Rudge, Karen A. Sankovich, Nancy A. Niemuth, Michael S. Anderson, Christopher S. Badorrek, Nick D. Skomrock, Chris M. Cirimotich & Carol L. Sabourin. (2019) Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLOS ONE 14:4, pages e0215457.
Crossref
Sergei I. Bazhan, Denis V. Antonets, Larisa I. Karpenko, Svetlana F. Oreshkova, Olga N. Kaplina, Ekaterina V. Starostina, Sergei G. Dudko, Sofia A. Fedotova & Alexander A. Ilyichev. (2019) In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice. Vaccines 7:2, pages 34.
Crossref
Denis Malvy, Anita K McElroy, Hilde de Clerck, Stephan Günther & Johan van Griensven. (2019) Ebola virus disease. The Lancet 393:10174, pages 936-948.
Crossref
Andrea Marzi & Chad E. Mire. (2019) Current Ebola Virus Vaccine Progress. BioDrugs 33:1, pages 9-14.
Crossref
Kerrie Vaughan, Xiaojun Xu, Bjoern Peters & Alessandro Sette. (2018) Investigation of Outbreak-Specific Nonsynonymous Mutations on Ebolavirus GP in the Context of Known Immune Reactivity. Journal of Immunology Research 2018, pages 1-11.
Crossref
Stephanie S Anguiano-Zarate, William E Matchett, Pramod N Nehete, Jagannadha K Sastry, Andrea Marzi & Michael A Barry. (2018) A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. The Journal of Infectious Diseases 218:12, pages 1883-1889.
Crossref
Heinz Feldmann, Friederike Feldmann & Andrea Marzi. (2018) Ebola: Lessons on Vaccine Development. Annual Review of Microbiology 72:1, pages 423-446.
Crossref
Kyoko Tomita, Fuminori Sakurai, Shunsuke Iizuka, Masahisa Hemmi, Keisaku Wakabayashi, Mitsuhiro Machitani, Masashi Tachibana, Kazufumi Katayama, Haruhiko Kamada & Hiroyuki Mizuguchi. (2018) Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration. Scientific Reports 8:1.
Crossref
Kuldeep Dhama, Kumaragurubaran Karthik, Rekha Khandia, Sandip Chakraborty, Ashok Munjal, Shyma K. Latheef, Deepak Kumar, Muthannan Andavar Ramakrishnan, Yashpal Singh Malik, Rajendra Singh, Satya Veer Singh Malik, Raj Kumar Singh & Wanpen Chaicumpa. (2018) Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Frontiers in Immunology 9.
Crossref
Qiang Guo, Jasper Fuk-Woo Chan, Vincent Kwok-Man Poon, Shipo Wu, Chris Chung-Sing Chan, Lihua Hou, Cyril Chik-Yan Yip, Changpeng Ren, Jian-Piao Cai, Mengsu Zhao, Anna Jinxia Zhang, Xiaohong Song, Kwok-Hung Chan, Busen Wang, Kin-Hang Kok, Yanbo Wen, Kwok-Yung Yuen & Wei Chen. (2018) Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models. The Journal of Infectious Diseases 218:3, pages 365-377.
Crossref
. (2018) Filovirus – Auslöser von hämorrhagischem Fieber. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 61:7, pages 894-907.
Crossref
Robert W. Cross, Chad E. Mire, Heinz Feldmann & Thomas W. Geisbert. (2018) Post-exposure treatments for Ebola and Marburg virus infections. Nature Reviews Drug Discovery 17:6, pages 413-434.
Crossref
William A Fischer2nd2nd, Pauline Vetter, Daniel G Bausch, Timothy Burgess, Richard T DaveyJrJr, Robert Fowler, Frederick G Hayden, Peter B Jahrling, Andre C Kalil, Douglas L Mayers, Aneesh K Mehta, Timothy M Uyeki & Michael Jacobs. (2018) Ebola virus disease: an update on post-exposure prophylaxis. The Lancet Infectious Diseases 18:6, pages e183-e192.
Crossref
Sarah Sebastian & Teresa Lambe. (2018) Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines 6:2, pages 29.
Crossref
Anita K McElroy, Elke Mühlberger & César Muñoz-Fontela. (2018) Immune barriers of Ebola virus infection. Current Opinion in Virology 28, pages 152-160.
Crossref
Ian R. Humphreys & Sarah Sebastian. (2018) Novel viral vectors in infectious diseases. Immunology 153:1, pages 1-9.
Crossref
Olugbenga Oluwagbemi & Olaitan Awe. (2018) A comparative computational genomics of Ebola Virus Disease strains: In-silico Insight for Ebola control. Informatics in Medicine Unlocked 12, pages 106-119.
Crossref
Michael P. Veve & Vasilios Athans. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 383 413 .
Jaskaran Singh, Thapa Komal, Sandeep Arora, Amarjot Kaur & Thakur Gurjeet Singh. (2017) Ebola Hemorrhagic Fever: Recent Update On Disease Status, Current Therapies And Advances In Treatment. Journal of Pharmaceutical Technology, Research and Management 5:2, pages 217-234.
Crossref
Ekaterina A. Koroleva, Natalie V. Kobets, Dmitrii N. Shcherbinin, Naylia A. Zigangirova, Maxim M. Shmarov, Amir I. Tukhvatulin, Denis Y. Logunov, Boris S. Naroditsky & Alexander L. Gintsburg. (2017) Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection . BioMed Research International 2017, pages 1-14.
Crossref
Elizabeth S. Higgs, Sheri A. Dubey, Beth A. G. Coller, Jakub K. Simon, Laura Bollinger, Robert A. Sorenson, Barthalomew Wilson, Martha C. Nason & Lisa E. Hensley. 2017. Marburg- and Ebolaviruses. Marburg- and Ebolaviruses 229 261 .
Marek Naczyk. (2021) Biotech, Biodefense and COVID-19 Vaccines in Russia’s National Security State. SSRN Electronic Journal.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.